Gilead Stock News

The trading price of Gilead Sciences Inc. (NASDAQ:GILD) floating lower at last check on Wednesday, December 15, trading at $70.38, -0.20% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Livforsakringsbolaget Skandia Omsesidigt reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 101,737 shares of the biopharmaceutical companys stock after selling 2,300 shares during the period. Livforsakringsbolaget Skandia Omsesidigts holdings in Gilead Sciences were worth $7,103,000 as of its most recent SEC []

Brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD) to post sales of $6.39 billion for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Gilead Sciences earnings, with the lowest sales estimate coming in at $6.22 billion and the highest estimate coming in at $6.69 billion. Gilead Sciences posted sales of []

Key Players covered in the Antiviral Drugs Market Research Report are Abbvie, Inc., Novartis AG, Gilead Sciences, Mylan N.V., GlaxoSmithKline, Merck & Co., Inc., Janssen Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Other key market players. Key Players covered in the Antiviral Drugs Market Research Report are Abbvie, Inc., Novartis AG, Gilead Sciences, Mylan N.V., GlaxoSmithKline, Merck & Co., Inc., Janssen Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Other key market players.

SHANGHAI , Dec. 15, 2021 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that the Ministry of Food and Drug Safety (MFDS) of South Korea accepted its New Drug Application (NDA) for Sacituzumab Govitecan ("SG") for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The MFDS in South Korea previously granted Fast Track Designation and Orphan Drug Designation to SG for the treatment of mTNBC in April 2021. "We''re extremely proud of this acceptance as breast cancer is the leading cause of death from cancer in South Korean women and one of the fastest growing cancers in the world," said Kerry Blanchard , MD, PhD, Chief Executive Officer of Everest Medicines. "Historically, women with metastatic TNBC have had fewer treatment options available and this application acceptance means we are one step closer in making SG available for women with this aggressive cancer in South Korea ." Under the trade name Trodelvy®, the U.S.

Toronto, Ontario–(Newsfile Corp. – December 14, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:… The post Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors first appeared on IT Business Net .

Washington Trust Bank raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 89.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,287 shares of the biopharmaceutical company’s stock after purchasing an additional 3,437 shares during the quarter. Washington Trust Bank’s […]

Toronto, Ontario--(Newsfile Corp. - December 14, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (''Awakn''), a biotechnology company developing and delivering psychedelic th

OLD National Bancorp IN increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,418 shares of the biopharmaceutical companys stock after purchasing an additional 195 shares during the quarter. OLD National []

The antibiotics are prescribed to kill the chlamydia bacteria. Doxycycline or azithromycin is the preferred treatments. Azithromycin is taken in one dose. Although doxycycline costs less, it must be taken for seven days. chlamydia can be cured with the right

Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD), churned out more data for its CAR-T Yescarta in first-line lymphoma patients.  The Company shared the data at the American Society of Hem

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced primary results from ZUMA-12, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel) as part of first-line treatment in patients with high-risk large B-cell lymphoma (LBCL). This is the first study to evaluate CAR T-cell therapy as part of first-line therapy in high-risk LBCL. The study is based on the desire to utilize potential curative treatment as

Westside Investment Management Inc. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the third quarter, Holdings Channel reports. The fund owned 52,034 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Gilead Sciences accounts for 1.8% of Westside Investment Management Inc.’s holdings, making the stock its 8th largest […]